FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312474795> ?p ?o ?g. }

• W4312474795 endingPage "14" @default.
• W4312474795 startingPage "11" @default.
• W4312474795 abstract "Introduction. Acute myeloid leukemia is a rare malignancy with an average age of 70 years at diagnosis. Until recently, five-year survival of younger patients with this disease, despite being treated with allogenic hematopoietic stem cell transplantation, was < 30%, while in patients older than 60 years it was < 10%. Treatment overview. Due to the heterogeneity of acute myeloid leukemia no new drugs for treating this disease have been introduced for decades. The introduction of new drugs began from 2017: midostaurin, gilteritinib, CPX351, enasidenib, ivosidenib, venetoclax, glasdegib, while gemtuzumab ozogamicin has been reintroduced. Modern treatment strategies require an individual approach, based on prognostic parameters such as cytogenetical and molecular profile of acute myeloid leukemia at diagnosis and the assessment of minimal residual disease evaluated after two cycles of chemotherapy. Moreover, determining the eligibility of patients for ??intensive?? treatment, based on functional status, comorbidities and geriatric assessment of older patients, is necessary. Regarding the treatment of acute promyelocytic leukemia, the combination of arsenic trioxide and all-trans retinoic acid is universally accepted as the standard of care for non-high risk patients (WBC < 10x109/L), while standard chemotherapy combined with all-trans retinoic acid is still used for high-risk patients (WBC >10x109/L). Conclusion. Novel therapeutic modalities, along with allo-HSCT have changed the outcome of AML patients. However, treating patients unfit for intensive chemotherapy, as well as patients with relapse/refractory disease, is still challenging." @default.
• W4312474795 created "2023-01-05" @default.
• W4312474795 creator A5000116987 @default.
• W4312474795 creator A5031033719 @default.
• W4312474795 creator A5035515667 @default.
• W4312474795 creator A5078936456 @default.
• W4312474795 creator A5089876539 @default.
• W4312474795 date "2022-01-01" @default.
• W4312474795 modified "2023-09-25" @default.
• W4312474795 title "Current strategies for the treatment of acute myeloid leukemia" @default.
• W4312474795 cites W1948328750 @default.
• W4312474795 cites W1981525265 @default.
• W4312474795 cites W2030773038 @default.
• W4312474795 cites W2090011336 @default.
• W4312474795 cites W2102205601 @default.
• W4312474795 cites W2153310476 @default.
• W4312474795 cites W2474389367 @default.
• W4312474795 cites W2511510229 @default.
• W4312474795 cites W2545758180 @default.
• W4312474795 cites W2559537906 @default.
• W4312474795 cites W2623089849 @default.
• W4312474795 cites W2715749014 @default.
• W4312474795 cites W2783450169 @default.
• W4312474795 cites W2790009201 @default.
• W4312474795 cites W2793968158 @default.
• W4312474795 cites W2808694334 @default.
• W4312474795 cites W2883399820 @default.
• W4312474795 cites W2898284215 @default.
• W4312474795 cites W2905344869 @default.
• W4312474795 cites W2914048049 @default.
• W4312474795 cites W2918095490 @default.
• W4312474795 cites W3177014409 @default.
• W4312474795 cites W3184559064 @default.
• W4312474795 cites W4211058078 @default.
• W4312474795 doi "https://doi.org/10.2298/mpns22s1011s" @default.
• W4312474795 hasPublicationYear "2022" @default.
• W4312474795 type Work @default.
• W4312474795 citedByCount "0" @default.
• W4312474795 crossrefType "journal-article" @default.
• W4312474795 hasAuthorship W4312474795A5000116987 @default.
• W4312474795 hasAuthorship W4312474795A5031033719 @default.
• W4312474795 hasAuthorship W4312474795A5035515667 @default.
• W4312474795 hasAuthorship W4312474795A5078936456 @default.
• W4312474795 hasAuthorship W4312474795A5089876539 @default.
• W4312474795 hasBestOaLocation W43124747951 @default.
• W4312474795 hasConcept C10205521 @default.
• W4312474795 hasConcept C104317684 @default.
• W4312474795 hasConcept C126322002 @default.
• W4312474795 hasConcept C143998085 @default.
• W4312474795 hasConcept C176290653 @default.
• W4312474795 hasConcept C185592680 @default.
• W4312474795 hasConcept C190283241 @default.
• W4312474795 hasConcept C2776601000 @default.
• W4312474795 hasConcept C2776694085 @default.
• W4312474795 hasConcept C2778461978 @default.
• W4312474795 hasConcept C2778623314 @default.
• W4312474795 hasConcept C2778729363 @default.
• W4312474795 hasConcept C2779282312 @default.
• W4312474795 hasConcept C2780386689 @default.
• W4312474795 hasConcept C2781121885 @default.
• W4312474795 hasConcept C28328180 @default.
• W4312474795 hasConcept C54355233 @default.
• W4312474795 hasConcept C55493867 @default.
• W4312474795 hasConcept C71924100 @default.
• W4312474795 hasConcept C86803240 @default.
• W4312474795 hasConceptScore W4312474795C10205521 @default.
• W4312474795 hasConceptScore W4312474795C104317684 @default.
• W4312474795 hasConceptScore W4312474795C126322002 @default.
• W4312474795 hasConceptScore W4312474795C143998085 @default.
• W4312474795 hasConceptScore W4312474795C176290653 @default.
• W4312474795 hasConceptScore W4312474795C185592680 @default.
• W4312474795 hasConceptScore W4312474795C190283241 @default.
• W4312474795 hasConceptScore W4312474795C2776601000 @default.
• W4312474795 hasConceptScore W4312474795C2776694085 @default.
• W4312474795 hasConceptScore W4312474795C2778461978 @default.
• W4312474795 hasConceptScore W4312474795C2778623314 @default.
• W4312474795 hasConceptScore W4312474795C2778729363 @default.
• W4312474795 hasConceptScore W4312474795C2779282312 @default.
• W4312474795 hasConceptScore W4312474795C2780386689 @default.
• W4312474795 hasConceptScore W4312474795C2781121885 @default.
• W4312474795 hasConceptScore W4312474795C28328180 @default.
• W4312474795 hasConceptScore W4312474795C54355233 @default.
• W4312474795 hasConceptScore W4312474795C55493867 @default.
• W4312474795 hasConceptScore W4312474795C71924100 @default.
• W4312474795 hasConceptScore W4312474795C86803240 @default.
• W4312474795 hasIssue "Suppl. 1" @default.
• W4312474795 hasLocation W43124747951 @default.
• W4312474795 hasOpenAccess W4312474795 @default.
• W4312474795 hasPrimaryLocation W43124747951 @default.
• W4312474795 hasRelatedWork W1973107024 @default.
• W4312474795 hasRelatedWork W2029654186 @default.
• W4312474795 hasRelatedWork W2031089660 @default.
• W4312474795 hasRelatedWork W2031611922 @default.
• W4312474795 hasRelatedWork W2044818650 @default.
• W4312474795 hasRelatedWork W2057100972 @default.
• W4312474795 hasRelatedWork W2316675843 @default.
• W4312474795 hasRelatedWork W2415900273 @default.
• W4312474795 hasRelatedWork W2912226095 @default.

• next